Abatacept

WASHINGTON — In this video, Ambreesh Chawla, MD, summarizes salient and practice-changing presentations in rheumatoid arthritis from ACR Convergence 2024.

WASHINGTON — Patients in early rheumatoid arthritis respond well to either abatacept or adalimumab, with the critical factor for both treatments being prompt initiation, according to data presented at ACR Convergence 2024.

WASHINGTON — In this video, Jeffrey A. Sparks, MD, MMSc, highlights an observational study investigating the impact of disease-modifying antirheumatic drugs on rheumatoid arthritis-associated interstitial lung disease.

Lower levels of S100 proteins at baseline predict better treatment response with abatacept in patients with polyarticular-course juvenile idiopathic arthritis, according to data published in Arthritis Research & Therapy.

In this Healio video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, discussed the top items from the February issue, including an exploration of how the placebo effect can be applied in rheumatology.

SCOTTSDALE, Ariz. — Patients with rheumatoid arthritis who had a decrease in a certain type of B cell that fails to express immunoglobulin D and CD27 saw clinical improvement with abatacept, according to data presented here.

Among patients with rheumatoid arthritis, the chosen course of therapy does not have an impact on the risk for developing a serious infection, according to data published in Rheumatology.

The FDA has approved a supplemental biologics licensing application from Bristol Myers Squibb expanding the indication of abatacept to include children aged 2 years and older with psoriatic arthritis, according to a company press release.

Patients with rheumatoid arthritis who receive abatacept or certolizumab pegol achieve clinical remission at higher rates than those receiving active conventional therapy, according to data published in Annals of the Rheumatic Diseases.